NASDAQ: SBFM 👥 Enters Into A Collaboration Agreement For Its K1.1 Anticancer mRNA Project! 🔬

Digital Asset Direct by Sunshine Biopharma Inc.

Detroit, Michigan | November 23, 2022 11:20 AM Eastern Standard Time

Sunshine Biopharma (NASDAQ: SBFM) has entered into a collaboration agreement with one of North America's leading lipid nanoparticle ("LNP") formulation companies to advance the development of Sunshine Biopharma's mRNA-based anticancer macromolecule, K1.1! Learn more about this collaboration and its significance in this video! Sunshine Biopharma focuses on the research, development & commercialization of life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. Visit Sunshine Biopharma: https://sunshinebiopharma.com/ https://investors.sunshinebiopharma.com/

Contact Details

Christine Petraglia - TraDigital IR

+1 917-633-8980

investors@sunshinebiopharma.com

Company Website

https://sunshinebiopharma.com/